To assess the efficacy and safety of retropubic tension-free vaginal tape (TVT) 17 years after implantation for the treatment of female pure stress urinary incontinence (SUI).
Introduction
The introduction of the retropubic tension-free vaginal tape (R-TVT) procedure by Ulmsten et al. [1] has irreversibly revolutionized the treatment of stress urinary incontinence (SUI). Thanks to their effectiveness and low invasiveness, mid-urethral slings (MUSs) have rapidly become the most popular surgical procedures for women affected by SUI [2] . A recent systematic review and meta-analysis of the literature focused on different surgical approaches for SUI and confirmed the superiority of MUSs in comparison with the other older surgical treatments (Burch colposuspension and the pubovaginal sling) [3] . While the short-and mediumterm results of MUSs are extremely encouraging and warrant their wide application [4] , the available evidence on their long-lasting benefits is still limited. Although the Public Health Notification issued by the US Food and Drug Administration regarding complications associated with the use of transvaginal mesh considered MUSs relatively safe, various working groups worldwide have emphasized the need to improve knowledge about their durability and long-term results [3] . Only eight studies in the literature have assessed the long-term outcomes of R-TVT, following patients for at least 10 years after surgery [2, [5] [6] [7] [8] [9] [10] [11] , and only one of them extends to >15 years of postoperative evaluation [10] . Moreover, these studies enrolled a heterogenous population, including women with recurrent SUI, mixed urinary incontinence and concomitant prolapse surgery. Even more importantly, follow-up evaluation was performed using telephone or internet interviews and a large percentage of patients were lost to follow-up.
The aim of the present study was to report the long-term subjective and objective outcomes of women who underwent an R-TVT procedure with a minimum 17-year follow-up, to assess the efficacy and the safety of this procedure. We also sought to investigate the predictive factors potentially involved in the risk of recurrence of SUI and the onset of de novo overactive bladder (OAB).
Patients and Methods
This was a prospective study performed in two urogynaecological units: the EOC -Beata Vergine Hospital, Mendrisio, Switzerland and the University of Insubria, Varese, Italy. Between January 1998 and January 2000, we enrolled all consecutive women who complained of pure SUI symptoms with urodynamically proven SUI. All women deemed eligible for surgical treatment were scheduled for an R-TVT procedure (Gynecare TVT System; Ethicon Inc., Somerville, NJ, USA). Exclusion criteria were as follows: women with a history of radical pelvic surgery, psychiatric and neurological disorders, concomitant vaginal prolapse greater than stage 1 according to the pelvic organ prolapse quantification system [12] , OAB symptoms, urodynamically proven detrusor overactivity, and postvoid residual urine volume >100 mL. Preoperative evaluation included medical history, physical examination, a voiding diary, urine analysis, and complete urodynamic testings. Physical examination was performed with the patient in the lithotomy position and pelvic organ prolapse was described during a maximal Valsalva manoeuvre according to the pelvic organ prolapse quantification system [12] . All women were evaluated with urodynamic studies as previously described [13] (including uroflowmetry, filling cystometry, Valsalva leak-point pressure measurement, and pressure/flow study) by a trained urogynaecologist, using a standardized protocol in accordance with the good urodynamic practice guidelines of the ICS [14] . Urethral hypermobility was defined by a Q-tip test result >30°. Women were included regardless of Q-tip test result and Valsalva leak-point pressure values. All methods, definitions and units were updated in agreement with the last version of the ICS standardization of terminology [15] . All the women also completed the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) [16] . All the TVT procedures were performed according to the technique originally described by Ulmsten et al. [1] . General or spinal anaesthesia was used in accordance with the anaesthesiological requirements and/or the patient's preference, as previously reported [17] . Postoperative evaluations were mandatory at 12, 60, 120, 180 and 204 months in the two centres and intermediate visits were scheduled at the physician's discretion. Every follow-up visit included a medical history, physical examination, voiding diary, stress test and evaluation of subjective satisfaction. A stress test was performed in the lithotomy and upright positions with a full bladder (ultrasonographic measurement > 400 mL). Objective cure was defined as the absence of urine leakage during the stress test. To define the subjective outcomes at 1, 5, 10, 15 and 17 years, all patients completed the ICIQ-SF, the Patient Global Impression of Improvement (PGI-I) scale (seven-point scale, with a range of responses from 1, 'very much improved' to 7, 'very much worse') [18] , and a patient-satisfaction scale (a single, self-answered, Likerttype scale of 0-10 that grades the patient's degree of satisfaction regarding continence: 0, 'not satisfied' to 10, 'satisfied') [19] . Subjective success was indicated both by 'very much improved or much improved' (PGI-I score ≤ 2) and by a patient-satisfaction score ≥8, as previously described in 2011 by Abdel-Fattah et al. [20] . Additional urodynamic studies were also performed when women complained of the onset of de novo overactive bladder (OAB) symptoms. For women with OAB, tolterodine 2 mg twice daily or solifenacin 5 mg once daily was administered for at least 12 weeks; the efficacy of this treatment was evaluated using the previously described three-point symptoms assessment scale. The Declaration of Helsinki was followed, and preoperative written informed consent for R-TVT implantation was obtained from all the women in this observational prospective evaluation.
Statistical Analysis
Statistical analysis was performed using IBM-SPSS v.17 for Windows (IBM Corp, Armonk, NY, USA). Continuous variables were reported as median and interquartile range. We used the chi-squared test and chi-squared test for trend to analyse and compare the surgical outcomes during followup. The chi-squared test for trend can better assess if the success of the surgical procedure tends to decrease over time, comparing the cure rates at the different follow-up visits (3-month, 1-, 5-, 10-, 15-and 17-year follow-ups). The null hypothesis was that there was no association between cure rate of TVT and time. One-way ANOVA was used to compare continuous series of variables in the comparison of the scores used to measure the subjective outcomes. The Cox proportional hazards model was used for univariate analysis to evaluate factors potentially affecting the risk of recurrence (subjective or objective) during the study period. P values < 0.05 were taken to indicate statistical significance. Analysis of success data was performed by plotting Kaplan-Meier survival curves, which were compared using the long-rank (Mantel-Cox) test. 
Results
During the study period, a total of 52 women with proven SUI, who fulfilled the inclusion criteria, underwent an R-TVT procedure. Figure 1 is a flowchart of the study. Baseline characteristics of the study participants are summarized in Table 1 . At the 17-year follow-up, 46 women (88.4%) were available for evaluation. Six women (11.6%) were lost to follow-up or were no longer evaluable: three (5.8%) died from medical causes unrelated to the TVT procedure (one after the 10-and two after the 15-year examination), two were lost after the 1-year and one after the 13-year follow-up). All the women lost to follow-up were subjectively cured at their last follow-up visit. Subjective and objective cure rates are summarized in Table 2 and shown in Fig. 2 . Table 3 reports the trend in the subjective outcomes scores over time. Longterm data showed no significant deterioration of either subjective or objective outcomes. At 17 years after surgery, 41 out of 46 women (89.1%) were subjectively cured (P for trend 0.43) and 42 out of 46 women (91.3%) were objectively cured (P for trend 0.50). Similarly, assuming that women lost to follow-up could have been included and that the outcome of their last visit was carried forward, 46 out of 52 patients (88.5%) would have been subjectively cured (P = 0.95) and 48 out of 52 patients (88.5%) would have been objectively cured (P = 0.43). The onset of de novo OAB symptoms was reported by 9.6% (5/52) and 32.6% (15/46) at the 3-month and 17-year follow-up, respectively. A significant trend for de novo OAB occurrence was registered at the 17-year follow-up (P = 0.02). Clavien-Dindo classification of long-term complications is shown in Table 4 . No patient required tape release or resection during these 17 years. No significant pelvic organ prolapse, vaginal bladder or urethral erosion, or de novo dyspareunia were recorded in the study population. The univariate analysis did not find any risk factor statistically associated with the recurrence of SUI.
Discussion
This study presents the combination of subjective and objective outcomes of R-TVT at 17-year follow-up in women with pure SUI. We found that R-TVT was a highly effective and safe procedure, with a long-lasting effectiveness over time.
After the warning issued by the US Food and Drug Administration in 2011, the use of vaginal mesh to correct pelvic organ prolapse and/or SUI has been widely questioned. A number of women have suffered serious, life-changing complications after prosthetic anti-pelvic organ prolapse surgery. Conversely, it has been shown that many women have benefitted from anti-incontinence MUS procedures. The Scottish Independent Review on the use, safety and efficacy of transvaginal mesh implants in the treatment of female SUI, recommends that women be offered all appropriate treatments (mesh and nonmesh) as well as the information to make informed choices.
It should be acknowledged that there is still a lack of information about long-term results and adverse effects of meshes for SUI. Few studies in the literature have evaluated outcomes of R-TVT with a follow-up of >10 years. Only Nilsson et al. [10] followed their patients for >15 years. They prospectively enrolled a cohort of 90 women who underwent the R-TVT procedure in three Nordic centres [10] . They reported a very high objective cure rate of 91.3%, assessed by cough stress test, and an 87.2% subjective cure rate, evaluated by the PGI-I, as well as by some specifically validated questionnaires. The study results did not change over time during the 17-year follow-up; however, only 51.1% of the patients (46/90) underwent an objective examination, and no • 46 women • 6 women lost to FU (3 deceased)
• 46 women • 6 women lost to FU (3 deceased) Fig. 1 Progress of patients across the study period. FU, follow-up; SUI, stress urinary incontinence. © 2018 The Authors BJU International © 2018 BJU International 115 urodynamic study evaluation was performed [2, 10] . Serati et al. [8] performed urodynamic studies during follow-up examinations. They reported, at 10-year follow-up, subjective, objective and urodynamic cure rates of 89.7%, 93.1% and 91.4%, respectively. Likewise, 11.5 years after R-TVT, Olsson et al. [6] reported objective and subjective cure rates of 84% and 77%, respectively, but again, a significant proportion of women included in that study were evaluated only by telephone or by internet, during the last follow-up visit [2, 11] . Recently, Serati et al. [2] observed excellent objective and subjective cure rates (90.9% and 85.5%, respectively) at 13-year follow-up after TVT in women with pure SUI. These extremely satisfactory results were confirmed at urodynamic evaluation of patients. A trend towards a reduction of the subjective satisfaction, however, was observed during the study period. In the present series, the subjective and objective efficacy of TVT did not change over the long term. It is interesting to note that no late mesh-related complications have appeared during the 17-year follow-up period. Nevertheless, we recorded a statistically significant growing trend of de novo OAB, especially in the late postoperative period (~30% at 17 years). This observation could reflect the aging of the patients rather than being a direct consequence of surgery. Regardless, the onset of OAB syndrome in women who received a MUS is a very relevant problem. In fact, it has been shown that antimuscarinic treatment is associated with significantly lower efficacy in women with de novo OAB after MUS placement [21] . These We recognize that the small sample size in the present study may be a limitation; however, we also emphasize that no larger investigations with a similar follow-up, evaluating both objective and subjective outcomes, are available in the literature.
In conclusion, consistent with previously published data on R-TVT, our results show that this procedure is highly effective, safe and has a long-lasting effectiveness over time.
Furthermore, we observed a very low complication rate over the follow-up period. Notably, we recorded a trend towards the occurrence of de novo OAB that became statistically significant at the 17-year follow-up. In our opinion, this is an important finding and should be taken into account when counselling patients.
